{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.41","upperLimit":"13.86","value":"11.04"},{"groupId":"OG001","lowerLimit":"3.06","upperLimit":"5.39","value":"4.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"Progression of disease is defined as the time from study start to the date of first documented progression of disease or death due to any cause. Progression of disease is defined by RECIST criteria: Progression = 20% increase in the sum of the longest diameter of all target lesions, from the smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or progression of non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consists of all patients who were randomized.","reportingStatus":"POSTED","timeFrame":"Time from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 17 August 2007, until cut-off date 28 February 2010","title":"Time to Progression Free Survival (PFS) Based as Per Investigator Using Kaplan-Meier Methodology","type":"PRIMARY","unitOfMeasure":"Months"}